Get started

Financials · HSCS

HeartSciences Inc. (HSCS) financials

For the twelve months ended Jul 31, 2026, HeartSciences Inc. reported $4.5K of revenue and -$10.26M of net income.

Revenue, TTM
$4.5K
Net income, TTM
-$10.26M
Net margin
-227024.2%
Cash
$29.9K
P/S
2572.56
Market cap
$11.6M
Annual revenue$4.3K
FY2022FY2026
Annual net income-$9.14M
FY2022FY2026
Annual free cash flow-$7.43M
FY2022FY2026

HSCS revenue and earnings growth

HSCS revenueQ1 2027$2.1K

Quarter YoY
+10.5%
FY YoY
-0.7%

HSCS revenue was $2.1K in fiscal Q1 2027 (ended Jul 31, 2026), up 10.5% from a year earlier. For the full fiscal 2026 it was $4.3K, down 0.7% from fiscal 2025. It rose in 1 of the last 4 fiscal years.

HSCS net incomeQ1 2027-$3.17M

HSCS net income was -$3.17M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$2.05M a year earlier. For the full fiscal 2026 it was -$9.14M, compared with -$8.77M in fiscal 2025.

HSCS EPSQ2 2026-$0.85

HSCS diluted EPS was -$0.85 in fiscal Q2 2026 (ended Oct 31, 2025). For the full fiscal 2025 it was -$9.34.

HSCS free cash flowQ4 2026-$1.68M

HSCS free cash flow was -$1.68M in fiscal Q4 2026 (ended Apr 30, 2026), compared with -$1.59M a year earlier. For the full fiscal 2026 it was -$7.43M, compared with -$7.42M in fiscal 2025.

Export CSV

Income statement

Income statement
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
Revenue$4.3K$4.3K$18.6K$5.2K$14.4K
Cost of revenue$1.8K$1.9K$6.1K$2.8K$7.9K
Gross profit$2.6K$2.5K$12.5K$2.4K$6.5K
Research and development$2.84M$4.39M$2.88M$2.46M$3.00M
Selling, general and admin$5.58M$3.97M$3.44M$3.65M$1.71M
Operating income-$8.41M-$8.35M-$6.31M-$6.11M-$4.71M
Interest expense$753.0K$500.5K$354.1K$243.2K$371.6K
Income tax$0$0---
Net income-$9.14M-$8.77M-$6.61M-$6.35M-$4.83M
EPS, basic-$3.48-$9.34-$18.74-$80.00-$145.00
EPS, diluted--$9.34-$18.74-$80.00-$145.00
Diluted shares-938,257352,52079,50633,188.92

Balance sheet

Balance sheet
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
Cash and equivalents$1.66M$1.10M$5.81M$1.66M$918.3K
Receivables-$4.3K--$2.3K
Inventory$655.6K$650.3K$629.2K$676.4K$674.1K
Current assets$2.58M$2.17M$7.35M$2.70M$1.93M
Total assets$5.26M$4.22M$9.50M$3.29M$2.09M
Current liabilities$4.86M$3.70M$1.75M$1.83M$3.47M
Total debt---$1.00M$6.07M
Total liabilities$5.04M$4.02M$2.19M$3.06M$8.15M
Shareholders' equity$226.1K$205.2K$7.32M$230.6K-$6.06M

Cash flow

Cash flow
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
Operating cash flow-$7.43M-$7.41M-$6.07M-$5.77M-$3.64M
Capital expenditures$3.6K$3.2K$64.5K$18.3K$1.9K
Free cash flow-$7.43M-$7.42M-$6.13M-$5.79M-$3.65M
Investing cash flow-$44.5K-$30.2K-$125.3K-$18.3K-$1.9K
Financing cash flow$8.03M$2.73M$10.34M$6.53M$3.84M
Stock-based compensation$1.31M$249.9K$405.0K$248.3K$68.4K

Key ratios

Key ratios
Line item
FY2026
Apr 30, 2026
FY2025
Apr 30, 2025
FY2024
Apr 30, 2024
FY2023
Apr 30, 2023
FY2022
Apr 30, 2022
Revenue growth, YoY-0.7%-76.6%261.2%-64.2%-
Gross margin59.1%56.8%67.3%45.7%45.1%
Operating margin-194787.4%-192013.1%-33902.0%-118698.3%-32765.6%
Net margin-211666.5%-201499.5%-35511.9%-123384.3%-33592.6%
Free cash flow margin-172036.6%-170486.2%-32981.9%-112463.8%-25367.5%
Return on equity-4044.0%-4272.2%-90.3%-2756.1%-
Return on assets-173.7%-207.6%-69.5%-193.3%-231.1%
Current ratio0.530.594.201.470.56
Debt to equity---4.34-

Source: XBRL data HeartSciences Inc. files with the SEC, latest filing dated Sep 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-100, first reported Jul 29, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

HSCS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
HSCS$4.5K--$10.26M-227024.2%$11.6M
ISRG$11.58B+20.5%$2.96B25.5%$156.00B
EW$6.67B+13.4%$1.02B15.3%$59.81B
STE$6.17B+8.1%$826.90M13.4%$24.97B
ZBH$8.57B+7.0%$767.30M9.0%$20.31B
MAS$7.67B+0.9%$926.00M12.1%$16.35B
SNN$6.16B+6.1%$625.00M10.1%$12.94B
ALGN$4.16B+4.4%$491.87M11.8%$12.28B
AIT$5.06B+8.5%$424.12M8.4%$10.92B

HSCS FAQ

7 questions
  • What is HSCS revenue?
    HeartSciences Inc. (HSCS) reported $4.5K of revenue for the twelve months ended Jul 31, 2026. Revenue for fiscal 2026 was $4.3K.
  • Is HSCS profitable?
    No. HeartSciences Inc. reported a net loss of $10.26M for the twelve months ended Jul 31, 2026.
  • How much cash and debt does HSCS have?
    HeartSciences Inc. reported $29.9K in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is HSCS revenue growing?
    HeartSciences Inc.'s revenue changed -0.7% in fiscal 2026, to $4.3K.
  • What is HSCS gross margin?
    HeartSciences Inc.'s gross profit was $2.8K on $4.5K of revenue for the twelve months ended Jul 31, 2026, a gross margin of 60.9%.
  • When did HSCS last report financial results?
    The latest statements here come from HeartSciences Inc.'s 10-Q filed on Sep 14, 2026, covering the period ended Jul 31, 2026.
  • Where does this HSCS financial data come from?
    Quantisnow builds these statements from the structured XBRL data HeartSciences Inc. files with the SEC. It is provided for information only and is not investment advice.